Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,338,875 papers from all fields of science
Search
Sign In
Create Free Account
HER4 Ag:PrThr:Pt:Tiss:Ord:Immune stain
Known as:
HER4 antigène [Arbitraire/Volume] Tissu ; Qualitatif ; Coloration immune
, HER4 Ag:PrThr:Moment:Weefsel en uitstrijkjes:Ordinaal:Immunokleuring
, HER4 Antigen:Presence or Threshold:Point in time:Tissue, unspecified:Ordinal:Immune stain
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Antigens
Body tissue
ERBB4 gene
Immune stain
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The correlation analysis of WWOX expression and cancer related genes in neuroblastoma- a real time RT-PCR study.
M. Nowakowska
,
E. Płuciennik
,
+4 authors
A. Bednarek
Acta Biochimica Polonica
2014
Corpus ID: 2533561
Neuroblastoma is one of the most common paediatric cancers, described as unpredictable due to diverse patterns of behaviour. WWOX…
Expand
2014
2014
The Role of her4 in Inner Ear Development and Its Relationship with Proneural Genes and Notch Signalling
Marija Radosevic
,
L. Fargas
,
B. Alsina
PLoS ONE
2014
Corpus ID: 16097143
The generation of sensory neurons and hair cells of the inner ear is under tight control. Different members of the Hairy and…
Expand
Review
2012
Review
2012
Epidermal growth factor receptor (EGFR) family members are dysregulated in a number of epithelial cell malignancies, including breast cancer[1]. The first three members of the family: EGFR/HER1, HER2…
Anna M. Misior
,
B. Diamond
2012
Corpus ID: 51747348
TITLE: HER4 Cyt1 and Cyt2 ,soforms 5egulate 7ranscription through 'ifferential ,nteraction with a 7ranscriptional 5egulator, Yap…
Expand
2011
2011
P1-12-23: HER4 Coexpression Is Associated with Improved Recurrence Free Survival in HER2−Positive, Herceptin Treated Patients.
G. Brockhoff
,
A. Machleidt
,
+5 authors
O. Ortmann
2011
Corpus ID: 72546894
Background: Individual therapy efficiency of HER2−positive metastatic and pre-metastatic breast cancer patients varies…
Expand
2011
2011
Die Bedeutung von Wachstumsfaktor-Rezeptortyrosinkinasen der EGFR-Familie bei Plattenepithelkarzinomen des Kopf-Hals-Bereichs
K. Brunner
2011
Corpus ID: 159966247
Hintergrund: Untersuchungen von Rezeptortyrosinkinasen der humanen epidermalen Wachstumsfaktor-Rezeptor (HER)-Familie stehen im…
Expand
2010
2010
Immunhistokemisk analysering av HER4 uttrycket och dess korrelation till prognos hos postmenopausala bröstcancerpatienter som randomiserats till behandling med eller utan Tamoxifen
Lotta Sjöquist
2010
Corpus ID: 107409199
Immunhistokemisk analysering av HER4 uttrycket och dess korrelation till prognos hos postmenopausala brostcancerpatienter som…
Expand
2009
2009
Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer
A. Sassen
,
S. Diermeier‐Daucher
,
+4 authors
G. Brockhoff
Breast Cancer Research
2009
Corpus ID: 4473709
IntroductionHER2 overexpression, or rather HER2 gene amplification, is indicative for Herceptin therapy in both metastatic and…
Expand
2006
2006
Generierung von zytotoxischen T-Zellen gegen das tumorassoziierte Antigen HER2
H. Conrad
2006
Corpus ID: 194611623
Die Rezeptortyrosinkinase Humaner Epidermaler Wachstumsfaktor 2 (HER2), ein bei verschiedenen Tumoren uberexprimiertes…
Expand
Highly Cited
1997
Highly Cited
1997
Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne Jc
,
Melhem Mf
,
+4 authors
R. Salup
The cancer journal from Scientific American
1997
Corpus ID: 10350484
BACKGROUND Prostate cancer is the most common cancer in American men and the second leading cause of cancer death. All clinical…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required